Faron Pharmaceuticals - Innovative medical solutions (Part 2)

Reason for Syrjälä’s notification: Dividend payments in kind. As a result: An acquisition or disposal of voting rights.

A similar operation as 2 weeks ago. Dividend payment to someone other than oneself. So, an ownership arrangement where shares are transferred out of a holding company. Technically something other than a sale, but the outcome is the same: Syrjälä’s official voting power and ownership stake in the company decrease.

There is no information about other Acme owners who could receive dividends. As capital-envious speculation, it’s good to make wealth arrangements when the target is undervalued, if taxes concern anyone in Monaco.

7 Likes